Clearside Biomedical to Present at the Ophthalmology Futures Retina Forum 2022

Rhea-AI Summary

Clearside Biomedical, Inc. (NASDAQ:CLSD) will have its Chief Medical Officer, Thomas A. Ciulla, present a company overview and participate as a panelist on August 31, 2022, at the Ophthalmology Futures Retina Forum 2022. Dr. Ciulla will discuss alternatives to intravitreal drug delivery for posterior segment diseases. The forum aims to connect various stakeholders in ophthalmology to foster innovation in eye care. Clearside is known for its revolutionary SCS injection platform, enabling targeted delivery of therapies for sight-threatening diseases.

ALPHARETTA, Ga., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS^®), announced today that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer will present a company overview and participate in an industry panel virtually during the Ophthalmology Futures Retina Forum 2022 on August 31, 2022.

• Dr. Ciulla will be a Panelist on the “Alternatives to Intravitreal Drug Delivery for Posterior Segment Diseases” session from 10:00 am – 10:30 am ET
• Dr. Ciulla will also present a Clearside Biomedical corporate overview

The Forum focuses on all aspects of global innovation in ophthalmology by connecting scientists, physicians, regulators, corporate leaders, venture capitalists and other investors who support the advancement of eye care. Conference information is available here and virtual registration to the event is complimentary.

About Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS^®). Clearside’s SCS injection platform, utilizing the Company’s proprietary SCS Microinjector^®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector and strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. Clearside’s first product, XIPERE^® (triamcinolone acetonide injectable suspension) for suprachoroidal use, is commercially available in the U.S. For more information, please visit www.clearsidebio.com.

Investor and Media Contacts:

Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206

Source: Clearside Biomedical, Inc.

 

FAQ

What is the main announcement from Clearside Biomedical on August 25, 2022?

Clearside Biomedical announced that its Chief Medical Officer, Thomas A. Ciulla, will present at the Ophthalmology Futures Retina Forum 2022 on August 31, 2022.

What topic will Dr. Thomas A. Ciulla discuss at the Ophthalmology Futures Retina Forum?

Dr. Ciulla will present on alternatives to intravitreal drug delivery for posterior segment diseases.

What is the focus of the Ophthalmology Futures Retina Forum 2022?

The Forum focuses on global innovation in ophthalmology, connecting key stakeholders to advance eye care.

What technology does Clearside Biomedical specialize in?

Clearside Biomedical specializes in the suprachoroidal space (SCS) injection platform for targeted therapy delivery to the back of the eye.

How can one register for the Ophthalmology Futures Retina Forum 2022?

Virtual registration for the Ophthalmology Futures Retina Forum 2022 is complimentary and available through the event's official website.